Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer

Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer
Poor Sleep Quality Negatively Impacts Some Adverse Effects in Patients With Advanced Cancer

Patients participating in early-phase clinical trials should be assessed for sleep quality, as poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance, according to a report published in the journal Cancer.1

Data on sleep quality for patients with advanced cancer participating in phase 1 clinical trials is limited. Poor sleep quality is not documented as an adverse event, and neither is its association with fatigue, one of the most frequently reported adverse effects.

In this report, authors assessed sleep, fatigue, symptom burden, and mood with the Pittsburgh Sleep Quality Index (PSQI), the Brief Fatigue Inventory, the MD Anderson Symptom Inventory (MDASI), and the Brief Profile of Mood States, respectively, in 256 patients recruited from an early-phase clinic for targeted therapy.

The study sample was 51.2% female, mean age 58 ± 0.8 years. Eastern Cooperative Oncology Group performance status, determined from medical records, was 0 or 1 in 90% of participants.

Sixty-four percent of the study sample were poor sleepers, with global PSQI score greater than 5. Higher levels of fatigue (P <.001), symptom burden (P <.001), and overall mood disturbance (P <.001) were seen in poor sleepers, compared with good sleepers. In addition, fatigue-related and symptom-related interference with daily activities (all P values <.001) was greater in poor sleepers than in good sleepers.

The MDASI disturbed-sleep item correlated well with the global PSQI score (Pearson's r = 0.679, P <.001), suggesting its usefulness as a screening tool for patient-reported sleep quality in early-phase clinical

The authors conclude that poor sleep quality was a significant problem for patients with advanced cancer who are participating in phase 1 clinical trials, and poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance. Therefore, sleep quality should be routinely assessed in these patients.

Reference

1. George GC, Iwuanyanwu EC, Anderson KO, et al. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer 2016 Jul 14. doi:10.1002/cncr.30182. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs